Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Episode 10: Dr. Ritesh Parajuli
Transcript
- 0:00Using liquid biopsies as predictive markers in breast
- 0:03cancer, this research and it's California team caught the
- 0:08attention of earlier.org. So much so, the team is awarded
- 0:11a grant to help fund the study. With more on this, here's Martha
- 0:15Kaley, founder and executive. Director of.
- 0:18Earlier.org and earlier detection for breast cancer.
- 0:22All right, folks, this is doctor para Julie from at the
- 0:27University of where's in comprehensive Cancer Center in
- 0:34California, right, Irvine. So his work has sprained my
- 0:40brain, but I hope he can straighten it out for me.
- 0:44I'm going to let him have the floor for this.
- 0:47This is a very interesting approach.
- 0:50And again, I have learned so many novel approaches for
- 0:56earlier detection of breast cancer.
- 0:58And this is just a way of us sharing that for all of you who
- 1:02have been kind enough to make contributions and to give you
- 1:07information, because I know you want that.
- 1:09So I'm just going to turn it over to you, Sir, and let you
- 1:13just tell them what your work is.
- 1:15Thank you very much. So you wanted to, would you go
- 1:18ahead and explain what, what your research is and what I know
- 1:23that we're talking about liquid biopsy and I found that so
- 1:26fascinating and the process of that.
- 1:30So could you help me with that? Sure.
- 1:32So I kind of got the meetings agenda and if if I may just give
- 1:37a brief introduction about myself.
- 1:39So my name is Ritesh Parajuli. I am a breast medical
- 1:43oncologist, currently an associate professor of medicine
- 1:47and the chair of the Breast Side Disease group at our Child
- 1:51Family Comprehensive Cancer Center at University of
- 1:54California, Irvine. I have the honor of receiving my
- 1:58training with an outstanding mentor, Doctor Mark Lippmann.
- 2:01So I take great pride in that my interest is ready drug drug
- 2:06development, combining multiple drug regimens to provide, you
- 2:10know, outcomes to my patients. But my translation research is
- 2:13focused on liquid biopsies as prognostic or predictive markers
- 2:19and and breast cancer, right? So with that background, what I
- 2:22would like to do here is, is give you a flavour of my
- 2:27translation research on on liquid biopsies.
- 2:30But prior to doing this, I just want to grab your attention in
- 2:35a, in a hypothesis called a seed and soil hypothesis, right?
- 2:41And if you, if we imagine the human breast as the soil, the
- 2:46seed is the cancer and the seed needs to grow.
- 2:51The seed cannot grow without a fertile soil.
- 2:54So in that fertile soil, there is a group of cells called
- 2:59cancer associated fibroblast. And there's a tremendous
- 3:04crosstalk between the breast cancer and the fibroblast in the
- 3:09human breast. So what we thought was when the
- 3:13seed gets detached from the breast and goes to the blood,
- 3:17and these circulating tumor cells go to different parts of
- 3:19the body and cause metastatic breast cancer, can these cells
- 3:24survive on their own? And do they bring along these
- 3:28cells from its own soil from the breast?
- 3:32Therefore, we hypothesize that these fibroblasts from the
- 3:37breast is also carried along with tumor cells with a seed and
- 3:42the soil could travel together in the blood from the breast, go
- 3:47to different parts of the body and cause metastatic breast
- 3:49cancer, right. So this hypothesis was looked at
- 3:54in some preclinical models that data has decently published.
- 3:58So when I was, you know, a fellow in Mark Lippman's lab,
- 4:02including others, we did our study where we looked at these
- 4:06cells in the blood and identified these cells as
- 4:11circulating cancer associated fibroblasts, not tumor cells,
- 4:16but C calves as we call it. And we showed that circulating
- 4:23fibroblasts or cancer associated fibroblasts are significantly
- 4:26elevated in patients with metastatic breast cancer, in
- 4:31patients with higher risk of metastasis, of developing
- 4:34metastasis, right. So we did a pilot process and
- 4:37then when I came to UCI, you know, and I carried on my
- 4:41translation work, we use the same concept to apply for a
- 4:46grant to the earlier foundation. And we were very fortunate that
- 4:50that the concept was funded. So in summary, my, my research
- 4:56is focused on a liquid biopsy, a biomarker called circulating
- 5:03cancer associated fibroblast was I'm now investigating to see if
- 5:08they prognosticate or they predict or detect metastatic
- 5:13breast cancer early on in the process.
- 5:16So that's really a bird's eye view of the work that I've been
- 5:20currently involved in. That is just that's really
- 5:24intriguing. So, so tell me, I'd like for you
- 5:30to address the fact of how important that these early seed
- 5:34grants are for researchers. That's just so critical, I
- 5:38think, have always thought that. And so would you reflect on that
- 5:43for me? That's a great question.
- 5:45So, so I think every concept starts with a hypothesis and a
- 5:50hypothesis cannot be tested unless there's a seed grant to
- 5:55support that hypothesis, right? And in this case, what you know
- 6:00the earlier foundation has done is is extremely noble and very
- 6:05appreciated. So when a hypothesis is
- 6:08generated and a preliminary data is generated based on these
- 6:12ballot grants, that is the first critical step till a prospective
- 6:19clinical trial is done and really to validate the
- 6:23hypothesis driven data in a clinical trial that has the
- 6:27potential of being practice changing for our patients with
- 6:31breast cancer or those who are at risk of breast cancer.
- 6:34So coming back to your question, C grants are tremendously
- 6:38important. They serve as the initial
- 6:41catalyst to jump start the project before even a clinical
- 6:45trial is is initiated. That's great.
- 6:49So and thinking about this liquid biopsy and I've followed
- 6:55that along. I thought that was very positive
- 6:58for a number of years ago. How far along do you think we
- 7:03are in that process of it sounded like your research was
- 7:08really had a lot to offer. There was a lot of promise in
- 7:13moving that whole approach forward.
- 7:18What's what's your reflection on that?
- 7:20Sure. So liquid.
- 7:22The research on liquid biopsy is very fluid in that aspect.
- 7:27What do I, what do I mean by that?
- 7:29There will be some, there will be many biomarkers that will
- 7:33come along, have come along, which can be validated, which
- 7:38cannot be validated. And at this current day and age,
- 7:41you know, circulating tumor cells have been established as
- 7:45liquid biopsies for breast cancer biomarkers in breast
- 7:48cancer. There's an emerging rule for
- 7:51circulating tumor DNA as biomarker in breast cancer or a
- 7:57detection. My, my research, however, is a
- 8:00little bit different. While I do look at CTCS or tumor
- 8:04cells in the blood and I look at your DNA in the blood, but I'm
- 8:08looking at, if you remember my first discussion, I said, I'm
- 8:11looking at the soil in the blood and see if the soil can increase
- 8:16survival of the seed and that could be perhaps more metastatic
- 8:20than the seed itself. So that's where we are at.
- 8:24So do you see in reading your work, it was like the cluster
- 8:32CTCS, is that what you're talking about?
- 8:34Fibroblast. Is that what you're discussing,
- 8:36right? That is correct.
- 8:39And so you see this as maybe sending up a red light that that
- 8:47that is maybe metastasizing or is it just detecting the
- 8:52presence or how do you see that working?
- 8:55Sure. So, so that's a great question.
- 8:58So the hypothesis is do circulating cancer fibroblasts
- 9:02by themselves or in clusters with CTCS, can this serve as
- 9:08early detectives or early detection biomarkers for
- 9:11metastatic breast cancer, Right. That's why the second hypothesis
- 9:15is do C calves or circulating fibroblasts serve as prognostic
- 9:21biomarkers along with or independent of CTCS in patients
- 9:26with that study breast cancer. So the grant that we got from
- 9:30the earlier foundation was extremely important to gather
- 9:34some pilot data. And I'm now in the process of
- 9:39collaborating with my Co investigators, Dr. Abe Lee and
- 9:43Doctor Ongshaw Agarwal at UCI and really launch a prospective
- 9:46clinical trial based on the ballot data we gather from the
- 9:52grant. And I'm really hoping that the
- 9:54next six months or so that clinical trial will be up and
- 9:57running. So it's very exciting.
- 9:59I hope you will let me know because I'm very excited about
- 10:02this. Now tell me about I, I like, I
- 10:05don't understand this exactly, but the let's see the the
- 10:09lateral cavity acoustic transducer device so that being
- 10:15used. Can you help me with that?
- 10:18Sure. So just like the way there are
- 10:22many biomarkers that are currently evolving and the
- 10:26biomarker that I'm proposing platforms and diagnostic devices
- 10:31that are used to isolate these. But these but these cells in the
- 10:36blood, right. So historically there is, there
- 10:39is still a platform called cell surge that isolates our shed
- 10:44from from the tissue to the blood.
- 10:48They undergo this process called epitheliumism chemo transition.
- 10:52Therefore, routine methodologies to pick up these cells may not
- 10:58be sensitive enough to actually measure the true metastatic load
- 11:03in the blood. Hence there's an unmet medical
- 11:06need to to design new methodologies which could be
- 11:10more sensitive than what's currently available.
- 11:12So one of my collaborators, Dr. Abe Lee has designed this, you
- 11:17know, LCAT platform where where cells like tumor cells are cut
- 11:23fibroblast or even immune cells can be isolated based on some
- 11:31sound frequencies. So that was pretty unique and
- 11:34novel and that was the whole basis of the hypothesis, the
- 11:39application from the grant. And now we we intend to use the
- 11:43same ail cat platform to launch this prospective trial that I
- 11:47briefly alluded to a couple of minutes ago.
- 11:50That's pretty awesome. Yeah, that is just, I found it
- 11:53just super amazing. So, so the the fibroblasts would
- 11:59be maybe more numerous than the circulating tumor cells.
- 12:07Is that the possibility of that? Well, the answer is, I think
- 12:12unless we do a prospective trial in a large number of patients
- 12:15that clinical, that question perhaps may not be adequately
- 12:19answered. But what we've shown, you know,
- 12:21based on the ground that we got from the earlier foundation is
- 12:25not only are CTCS increased in the numbers in patients with
- 12:30metastatic breast cancer, but so are cancer associated fibroblast
- 12:36simultaneously higher in the blood alongside CTCS in
- 12:41metastatic breast cancer. Now the important question is in
- 12:45patients who don't have metastatic breast cancer, can
- 12:48fibroblast along with CTCS predict metastasis?
- 12:53And that would be a very cool and novel concept I pop to to
- 12:56investigate. Right.
- 12:58That, that's just fascinating. So how, how far along do we
- 13:02think that this whole approach with the liquid biopsies, I mean
- 13:08research obviously steps on top of research, steps on top of
- 13:12research in the in the climbing of the steps with this liquid
- 13:17biopsy research, how do you feel we are progressing with that?
- 13:23I think we are doing a phenomenal job and a little bit
- 13:26of historical perspective I think is is important here.
- 13:29If we look at how circulating tumor cells were first
- 13:33identified, investigated and enumerated, what used to be
- 13:37simple enumeration of CTC's in the last 20 years has evolved to
- 13:43what is called as single cell sequencing.
- 13:46We are now able to isolate a single tumor cell and analyze
- 13:50its data in the genomic level, in the single cell level.
- 13:54So enumeration has moved to genomics in the last 20 years or
- 13:59so and that's fascinating. I intend to really understand
- 14:03calves in the blood in a single cell level, but that is a
- 14:07Herculean task to undertake. I think that moving forward,
- 14:11along with CTCS and C caps, the role of CTDNA will continue to
- 14:16evolve. And eventually, you know, in the
- 14:20modern day and age of, you know, artificial intelligence, we will
- 14:23eventually start integrating AIS and see how these companion
- 14:27diagnostic platforms and liquid biopsies can further be
- 14:31prospectively validated. So I think it's liquid biopsies
- 14:34have a promising future. Good.
- 14:37I, I, I have always felt that there was such promise in that.
- 14:41But the, the, the involvement of it is quite complex, obviously
- 14:47that you were seeing. And I just, I think your work is
- 14:50just fascinating. And I'm so happy to hear that
- 14:55you see AI being a helpful asset.
- 14:59I think that's just going to help us explode with
- 15:01information. So is there anything you want to
- 15:05share any kind of work that you're very excited and further
- 15:09with that or are you looking, are you interested in other
- 15:14funding? Obviously we're always
- 15:16interested in funding, right? So, So what do you have on your
- 15:20that you're looking at looking forward to?
- 15:23Sure. So, so thank you for that.
- 15:26Thank you for that question. So the fund that we received
- 15:29from the earlier grant, earlier foundation was critical in
- 15:33generating this pilot data and reinforcing what we knew the
- 15:38last few years. So we have a pilot data from
- 15:44three different microfluidic platforms across 100 patients or
- 15:49so. But unless we do a prospective
- 15:52clinical trial, validating it's predictability, prognostic value
- 15:59tends to be a challenge. So the next trial that I'm about
- 16:02to sort of write and, and, and run this at my institution will
- 16:07require funding from, you know, intramural agencies at UCI or
- 16:11perhaps beyond. So my goal in the next 6 to 8
- 16:14months is not just to write the trial, but also to apply for
- 16:18extramural funding that can fund this concept of this prospective
- 16:22trial for the next five years. Right.
- 16:25Well, I have to say I our medical advisory committee is
- 16:30remarkable to have identified your work.
- 16:35They worked very diligently at evaluating the request.
- 16:41And so I'm very proud of their work.
- 16:44I wish I were smart enough to do it, but I just think that they
- 16:49have done a wonderful job and we're just so happy to have
- 16:52connected with you. And thank you so much for
- 16:55sharing the information. And I can't thank you enough for
- 16:58that. So I hope things go well.
- 17:02It is it is an honor to be a part of this team and thank you
- 17:05for all the great work you and a team have been doing.
- 17:07So appreciate that. Thank you very much.
- 17:10Have a good day. Thank you.
- 17:11So have a. Great day too, bye bye.
- 17:13Bye. This episode of Isn't That
- 17:16Interesting was made possible thanks to volunteers and donors
- 17:19just like you. It was hosted by Martha Kaley,
- 17:22founderofearlier.org and edited by Liam Mcburney.
- 17:26I'm Valerie Amsterdam, reminding you that for the last 30 years,
- 17:30this is North Carolina based organization has helped fund
- 17:33groundbreaking research all over the world, from molecular
- 17:37imaging to a sensitive blood test for breast cancer.
- 17:40Plain and simple, earlier detection saves lives and you
- 17:44can help host a fundraising event.
- 17:46Make a donation for Volunteer your time.
- 17:49You can find us not only on the web but on Facebook and
- 17:51Instagram too. Let's change the picture of
- 17:54breast cancer together.